Literature DB >> 28510139

Development of target delivery system based on actinomycin class drugs and recombinant alpha-fetoprotein.

E D Nikolskaya1, O A Zhunina2, N G Yabbarov2, V I Shvets3, B I Krugliy2, E S Severin2.   

Abstract

A recombinant alpha-fetoprotein (rAFP) was obtained in the yeast P. pastoris system, and its functional activity was confirmed. A method for producing polymer particles loaded with dactinomycin was developed, and a conjugate of these nanoparticles with rAFP was synthesized. The efficiency of the obtained conjugate on the HeLa, SKOV3, and MG-63 tumor cells and the absence of toxicity on the normal cells was shown. Experiments in vivo demonstrated a significant increase in the antitumor efficacy of the conjugate at a lower general toxicity as compared to the commercially available dactinomycin.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28510139     DOI: 10.1134/S1607672917020156

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  2 in total

1.  Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro.

Authors:  S E Severin; I I Shmyrev; G A Posypanova; V K Sologub; R Nakachian; J Andreani; E S Severin
Journal:  Biochem Mol Biol Int       Date:  1995-10

2.  Recombinant alpha-fetoprotein C-terminal fragment: the new recombinant vector for targeted delivery.

Authors:  Galina A Posypanova; Neonila V Gorokhovets; Vladimir A Makarov; Ludmila V Savvateeva; Natalya N Kireeva; Sergey E Severin; Evgeny S Severin
Journal:  J Drug Target       Date:  2008-05       Impact factor: 5.121

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.